Ruiwen Zhang et Robert L. Boblitt ex universitate Houston novum cancrum pancreaticum medicamento elaboraverunt. The research was published in the Journal of Cancer Research. The drug targets two genes at the same time, and this breakthrough achievement is of great significance for the treatment of aggressive and deadly pancreaticum cancer,.
Quod pharmacum est etiam expectatur ad a compage ad progressionem medicinae tractare de quavis alia forma cancer et aliis morbis. Pancreaticum cancer est cum pancreaticum cellulis incipiunt develop et multiplicamini et imperium in massas confunditur, atque inde aliae partes corporis cancer cellulis potest invadendi. Maxime carcinomata incipit area in pancreas qui digestive enzymes operatur. Signa etiam stomacho aut repentina damnum et morbo (selu). In addition, a person’s urine may appear dark yellow and itchy skin. There are two oncogenes associated with pancreatic cancer. There are two main ways for the drug to inhibit pancreatic cancer. They activate the nuclear factor of T cell 1 (NFAT1) and murine double microparticle 2 (MDM2), respectively. The latter gene regulates a tuberculum suppressor gene called p53. When there is no tumor suppressor p53, MDM2 can cause cancer. NFAT1 is used to up-regulate the expression of MDM2, thereby promoting tumor growth. Factors related to diet, nutrition and the environment can lead to increased levels of these factors in the cell.
Et de hoc inventionis, Dr. Zhang dixit quod orci necessitates oriuntur novae atque efficax, et tutum curatio medicinae in pancreaticum cancer et nondum fuerat occurrit. Puta major Inventiones nostri promotionem in cancer research. Et addidit: «target Most pharmaca unum elementum nisi. Nos identificatur a se compositis scuta duo cancer-related genes. 'In compositis autem novum medicamento est synthetica MA242. Medicamentum sumere possunt simul duo proteins, ita ut meliorem efficientiam occisio summo tumore effundunt.
